{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,11]],"date-time":"2026-04-11T10:40:41Z","timestamp":1775904041465,"version":"3.50.1"},"reference-count":21,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2014,7,3]],"date-time":"2014-07-03T00:00:00Z","timestamp":1404345600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Pharmacokinet"],"published-print":{"date-parts":[[2014,8]]},"DOI":"10.1007\/s40262-014-0149-y","type":"journal-article","created":{"date-parts":[[2014,7,2]],"date-time":"2014-07-02T13:02:40Z","timestamp":1404306160000},"page":"731-740","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Pharmacokinetics of Orally Administered Duloxetine in Children and Adolescents with Major Depressive Disorder"],"prefix":"10.1007","volume":"53","author":[{"given":"Evelyn D.","family":"Lobo","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tonya","family":"Quinlan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Apurva","family":"Prakash","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2014,7,3]]},"reference":[{"issue":"7","key":"149_CR1","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1097\/00004583-199607000-00012","volume":"35","author":"D Shaffer","year":"1996","unstructured":"Shaffer D, Fisher P, Dulcan MK, et al. The NIMH Diagnostic Interview Schedule for Children Version 2.3 (DISC-2.3): description, acceptability, prevalence rates, and performance in the MECA Study. Methods for the Epidemiology of Child and Adolescent Mental Disorders Study. J Am Acad Child Adolesc Psychiatry. 1996;35(7):865\u201377.","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"issue":"2","key":"149_CR2","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/j.jpeds.2005.09.028","volume":"148","author":"PG Hammerness","year":"2006","unstructured":"Hammerness PG, Vivas FM, Gellar DA. Selective serotonin reuptake inhibitors in pediatric psychopharmacology: a review of the evidence. J Pediatr. 2006;148(2):158\u201365.","journal-title":"J Pediatr"},{"key":"149_CR3","unstructured":"Prozac\u00ae (fluoxetine hydrochloride tablets) full prescribing information. Prozac website [online]. Available at http:\/\/www.fluoxetine60.com\/prescribing-information.php . Updated 2011. Accessed Jun 2011."},{"key":"149_CR4","unstructured":"Lexapro\u00ae (escitalopram oxalate tablets) full prescribing information. Forest Laboratories website [online]. Available at http:\/\/www.frx.com\/products\/lexapro.aspx . Updated 2011. Accessed May 2011."},{"issue":"8","key":"149_CR5","doi-asserted-by":"crossref","first-page":"535","DOI":"10.2165\/00002018-200427080-00006","volume":"27","author":"KN Atuah","year":"2004","unstructured":"Atuah KN, Hughes D, Pirmohamed M. Clinical pharmacology: special safety considerations in drug development and pharmacovigilance. Drug Saf. 2004;27(8):535\u201354.","journal-title":"Drug Saf"},{"issue":"1\u20132","key":"149_CR6","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1089\/cap.2006.16.131","volume":"16","author":"RL Findling","year":"2006","unstructured":"Findling RL, McNamara NK, Stansbrey RJ, et al. The relevance of pharmacokinetic studies in designing efficacy trials in juvenile major depression. J Child Adolesc Psychopharmacol. 2006;16(1\u20132):131\u201345.","journal-title":"J Child Adolesc Psychopharmacol"},{"key":"149_CR7","unstructured":"Cymbalta\u00ae (duloxetine hydrochloride capsules) full prescribing information. Cymbalta website [online]. Available at http:\/\/www.cymbalta.com\/Pages\/index.aspx . Updated 2012. Accessed Nov 2012."},{"issue":"1","key":"149_CR8","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1089\/cap.2011.0072","volume":"22","author":"A Prakash","year":"2012","unstructured":"Prakash A, Lobo E, Kratochvil CJ, et al. An open-label safety and pharmacokinetics study of duloxetine in pediatric patients with major depression. J Child Adolesc Psychopharmacol. 2012;22(1):48\u201355.","journal-title":"J Child Adolesc Psychopharmacol"},{"key":"149_CR9","doi-asserted-by":"crossref","unstructured":"Emslie G, Prakash A, Zhang Q, et al. A double-blind, efficacy and safety study of duloxetine fixed doses in children and adolescents with major depressive disorder. J Child Adolesc Psychopharmacol. 2014;24(4):170\u20139.","DOI":"10.1089\/cap.2013.0096"},{"key":"149_CR10","doi-asserted-by":"crossref","unstructured":"Atkinson SD, Prakash A, Zhang Q, et al. A double-blind, efficacy and safety study of duloxetine flexible dosing in children and adolescents with major depressive disorder. J Child Adolesc Psychopharmacol. 2014;24(4):180\u20139.","DOI":"10.1089\/cap.2013.0146"},{"key":"149_CR11","unstructured":"Beal S, Sheiner LB, Boeckmann A, et al. NONMEM user\u2019s guide. (1989\u20132011). Ellicott City (MD): Icon Development Solutions; 2011."},{"issue":"3","key":"149_CR12","doi-asserted-by":"crossref","first-page":"189","DOI":"10.2165\/00003088-200948030-00005","volume":"48","author":"ED Lobo","year":"2009","unstructured":"Lobo ED, Quinlan T, O\u2019Brien L, et al. Population pharmacokinetics of orally administered duloxetine in patients: implications for dosing recommendation. Clin Pharmacokinet. 2009;48(3):189\u201397.","journal-title":"Clin Pharmacokinet"},{"key":"149_CR13","unstructured":"O\u2019Brien L, Hewitt R, Heathman M, et al. Challenging the robustness of a population pharmacokinetic model obtained from a phase III raloxifene study [abstract no. 3548.] American Association of Pharmaceutical Sciences Annual Meeting; 1998 Nov 15\u201319; San Francisco (CA)."},{"issue":"4","key":"149_CR14","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1097\/00004583-199804000-00016","volume":"37","author":"J Alderman","year":"1998","unstructured":"Alderman J, Wolkow R, Chung M, et al. Sertraline treatment of children and adolescents with obsessive-compulsive disorder or depression: pharmacokinetics, tolerability, and efficacy. J Am Acad Child Adolesc Psychiatry. 1998;37(4):386\u201394.","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"issue":"8","key":"149_CR15","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1097\/00004583-199908000-00010","volume":"38","author":"RL Findling","year":"1999","unstructured":"Findling RL, Reed MD, Myers C, et al. Paroxetine pharmacokinetics in depressed children and adolescents. J Am Acad Child Adolesc Psychiatry. 1999;38(8):952\u20139.","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"issue":"6","key":"149_CR16","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1097\/00004714-200212000-00006","volume":"22","author":"TE Wilens","year":"2002","unstructured":"Wilens TE, Cohen L, Biederman J, et al. Fluoxetine pharmacokinetics in pediatric patients. J Clin Psychopharmacol. 2002;22(6):568\u201375.","journal-title":"J Clin Psychopharmacol"},{"issue":"3","key":"149_CR17","doi-asserted-by":"crossref","first-page":"191","DOI":"10.2165\/00003088-200847030-00005","volume":"47","author":"ED Lobo","year":"2008","unstructured":"Lobo ED, Bergstrom RF, Reddy S, et al. In vitro and in vivo evaluations of cytochrome P450 1A2 interactions with duloxetine. Clin Pharmacokinet. 2008;47(3):191\u2013202.","journal-title":"Clin Pharmacokinet"},{"issue":"3","key":"149_CR18","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1067\/mcp.2003.28","volume":"73","author":"MH Skinner","year":"2003","unstructured":"Skinner MH, Kuan HY, Pan A, et al. Duloxetine is both an inhibitor and a substrate of cytochrome P4502D6 in healthy volunteers. Clin Pharmacol Ther. 2003;73(3):170\u20137.","journal-title":"Clin Pharmacol Ther"},{"issue":"3","key":"149_CR19","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1046\/j.1472-8206.2003.00140.x","volume":"17","author":"M Strolin Benedetti","year":"2003","unstructured":"Strolin Benedetti M, Baltes EL. Drug metabolism and disposition in children. Fundam Clin Pharmacol. 2003;17(3):281\u201399.","journal-title":"Fundam Clin Pharmacol"},{"key":"149_CR20","unstructured":"Zoloft\u00ae (sertraline hydrochloride tablets and oral concentrate) full prescribing information. Zoloft website [online]. Available at http:\/\/www.zoloft.com\/ . Updated 2012. Accessed May 2012."},{"key":"149_CR21","unstructured":"Paxil\u00ae (paroxetine hydrochloride tablets and oral suspension) full prescribing information. Paxil website [online]. Available at http:\/\/us.gsk.com\/products\/assets\/us_paxil.pdf . Updated 2011. Accessed July 2011."}],"container-title":["Clinical Pharmacokinetics"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40262-014-0149-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40262-014-0149-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40262-014-0149-y","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,6,2]],"date-time":"2019-06-02T19:41:07Z","timestamp":1559504467000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40262-014-0149-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,7,3]]},"references-count":21,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2014,8]]}},"alternative-id":["149"],"URL":"https:\/\/doi.org\/10.1007\/s40262-014-0149-y","relation":{},"ISSN":["0312-5963","1179-1926"],"issn-type":[{"value":"0312-5963","type":"print"},{"value":"1179-1926","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,7,3]]}}}